Allmed Medical Soars 10.03%, Hits Intraday High of CNY 11.30

Allmed Medical Products Co., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant surge in its stock price, gaining 10.03% on March 13, 2026. The stock reached an intraday high of CNY 11.30, showcasing strong performance compared to the broader market, as the China Shanghai Composite index declined by 0.82% on the same day. Over the past year, Allmed Medical has demonstrated robust growth, with a notable 29.29% increase in stock value, outpacing the Shanghai Composite's 21.93% gain. The company's financial health is underscored by a remarkable net profit growth of 31.44% and a consistent positive performance over the last four quarters. Key financial metrics include a return on equity (ROE) of 11.00% and a price-to-book ratio of 1.67, indicating an attractive valuation. Additionally, Allmed Medical's operating cash flow reached a record CNY 750.96 million, while its debt-equity ratio stands at a low -9.92%, reflecting a solid balance sheet. With a dividend yield of 0.55%, the company continues to position itself favorably within its industry.